Navigation Links
Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
Date:4/27/2012

M. Catherine Lee, M.D., breast cancer researcher and assistant member at Moffitt Cancer Center, has received a $100,000 grant from General Electric's $100 million healthymagination Challenge to develop genetic tools to investigate an individual's genetic makeup to determine if they are predisposed to develop or resist breast cancer metastasis.

GE's healthymagination grant awarding initiative focuses on "finding new ideas that accelerate innovation in early diagnosis, patient stratification, and the personalized treatment of breast cancer."

Lee's successful proposal, "Heritable Markers of Metastasis in Patients Diagnosed with Breast Cancer," was based on what Lee describes as "significant evidence for specific genetic variations associated with an increased risk of cancer metastasis."

According to Lee, the tumor in breast cancer is not the lethal element. Rather, it is the development and progression of breast cancer to other organs - called metastasis - that determines outcomes and survival. A number of genes and variations of those genes involved in the development of metastatic breast cancer have been identified.

Metastatic breast cancer is deadly. In 2011, an estimated 230,430 women in the United States were diagnosed with breast cancer. Of them, approximately 40,000 will die from metastatic disease.

"We suspect that an individual's genetic makeup can predispose them to develop or resist breast cancer spread," Lee said. "Our approach will be to evaluate genetic variations known as single nucleotide polymorphisms, or SNPs, in patients being treated for breast cancer."

Moffitt collects and banks tissue samples from patients who volunteer to be part of the research. From those tissue banks, the researchers have already identified 150 women treated at Moffitt's Comprehensive Breast Program who developed metastatic disease within five years of follow-up. This group will be compared to a control group of women who did not develop metastatic disease after five years of follow-up.

The task for Moffitt researchers will be to evaluate inherited changes in DNA that are predictive for and identify inherited risk for developing or resisting breast cancer metastasis.

"We hope to identify biologic markers of metastasis to help classify those facing a higher metastasis risk," Lee said. "We also aim to improve therapeutic decision-making and ability to better predict outcomes after a breast cancer diagnosis."

The study falls under Moffitt's mission to offer personalized medicine to patients, a treatment plan by which an individual's disease is treated based on the patient's unique genetic makeup.

"Our ultimate goal is to develop a cheek swab test for patients diagnosed with breast cancer to be able to quickly guide treatment decisions based on their inherited predisposition to develop advanced disease," Lee said.

The Moffitt research team on the grant includes Johnathan Lancaster, M.D., Ph.D.; Ya-Yu Tsai, Ph.D.; and Thomas Sellers, Ph.D., M.P.H., Moffitt executive vice president and director of the Moffitt Research Institute. The research team is also collaborating with laboratories at the National Cancer Institute in Washington, D.C.


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
2. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
3. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
4. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
5. Moffitt Cancer Center researchers find more clues to causes of breast cancer
6. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
7. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
8. Moffitt Cancer Center researchers find men less willing to be screened for cancer
9. Moffitt Cancer Center researchers find MK1775 active against sarcomas
10. Moffitt researchers will be strong participants in American Society of Hematology meeting
11. Moffitt Cancer Center researchers find potential target for treating metastatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Middletown, PA (PRWEB) , ... February 12, 2016 , ... ... year’s event will be held in Anaheim, CA at the Anaheim Convention Center. Almost ... they can see new therapy products in action, learn more about their chosen field ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... announced that nominations have closed for the ISE Southeast Awards 2016. Finalists and ... announced at the ISE® Southeast Executive Forum and Awards Gala on March 15, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is killed, injured or loses ... Penn Burn Center, part of the Allegheny Health Network, has partnered with Etna ... “Space Heaters Need Space” campaign. , “Space Heaters Need Space” aims to ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a family owned insurance company ... launching a cooperative charity drive with the Tarrant Area Food Bank in the hopes ... and families in need, the Tarrant County Food Bank offers hope and security to ...
(Date:2/12/2016)... ... 2016 , ... Young Asset Protection, a full service insurance ... latest charity campaign in their community enrichment program. Art Expression utilizes after-school programs ... are currently being accepted at: http://artexpressioninc.org/ . , Art Expression is a ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
(Date:2/11/2016)... 2016 The primary goal of this research ... on the usage of liquid biopsy. Key information the ... - Timeframe of liquid biopsy adoption amidst future users ... organization type - Sample inflow to conduct liquid biopsy ... serum, and so on. - Correlation analysis of sample ...
(Date:2/11/2016)... IRVINE, Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: ... quarter ended December 31, 2015. The Company also filed its ... fiscal year 2016 with the Securities and Exchange Commission today. ... December 31, 2015 --> --> ... 2015 increased $2.6 million, or 95%, to $5.4 million from ...
Breaking Medicine Technology: